Log in

Relevant bibliographies by topics / Antifibrotic Agents

Contents

Journal articles

Academic literature on the topic 'Antifibrotic Agents'

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antifibrotic Agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antifibrotic Agents"

1

Albanis, E., and S. L. Friedman. "Antifibrotic Agents for Liver Disease." American Journal of Transplantation 6, no. 1 (2006): 12–19. http://dx.doi.org/10.1111/j.1600-6143.2005.01143.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

LaCamera, Peter P., Susan L. Limb, Tmirah Haselkorn, Elizabeth A. Morgenthien, John L. Stauffer, and Mark L. Wencel. "Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis." Chronic Respiratory Disease 16 (January 1, 2019): 147997311987967. http://dx.doi.org/10.1177/1479973119879678.

Full text

Abstract:

Pirfenidone and nintedanib are oral antifibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF). Real-world data on factors that influence IPF treatment decisions are limited. Physician characteristics associated with antifibrotic therapy initiation following an IPF diagnosis were examined in a sample of US pulmonologists. An online, self-administered survey was fielded to pulmonologists between April 10, 2017, and May 17, 2017. Pulmonologists were included if they spent >20% of their time in direct patient care and had ≥5 patients with IPF receiving antifibrotics.

APA, Harvard, Vancouver, ISO, and other styles

3

Skuta, Gregory L. "Antifibrotic Agents in Glaucoma Filtering Surgery." International Ophthalmology Clinics 33, no. 4 (1993): 165–82. http://dx.doi.org/10.1097/00004397-199303340-00014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Oishi, Keiji, Tsunahiko Hirano, Yoriyuki Murata, et al. "Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study." Therapeutic Advances in Respiratory Disease 13 (January 2019): 175346661987289. http://dx.doi.org/10.1177/1753466619872890.

Full text

Abstract:

Background: In patients with idiopathic pulmonary fibrosis (IPF), continuing treatment with antifibrotic agents is crucial to decrease the reduction of forced vital capacity and mortality rate. However, predictive factors for the discontinuation of antifibrotic agents are unknown. This study aims to investigate the clinical characteristics and predictive factors for the discontinuation of antifibrotic agents in patients with IPF. Methods: This was a double-center retrospective study that enrolled patients with IPF treated with pirfenidone or nintedanib between 2009 and 2017. We compared clinic

APA, Harvard, Vancouver, ISO, and other styles

5

Kawada, Norifumi. "Antifibrotic agents emerging from traditional herbal medicine." Arab Journal of Gastroenterology 10, no. 4 (2010): S21—S22. http://dx.doi.org/10.1016/j.ajg.2009.12.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Geismar, Lois S., Janet S. Kerr, Robert L. Trelstad, and David J. Riley. "Treatment of experimental silicosis with antifibrotic agents." Toxicology 53, no. 2-3 (1988): 331–44. http://dx.doi.org/10.1016/0300-483x(88)90225-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Grotendorst, Gary R. "Identification and development of novel antifibrotic agents." Expert Opinion on Investigational Drugs 6, no. 6 (1997): 777–81. http://dx.doi.org/10.1517/13543784.6.6.777.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Jegal, Yangjin, Jong Sun Park, Song Yee Kim, et al. "Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry." Tuberculosis and Respiratory Diseases 85, no. 2 (2022): 185–94. http://dx.doi.org/10.4046/trd.2021.0123.

Full text

Abstract:

Background: The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the recent decade. The aim of this study was to describe recent clinical characteristics of Korean IPF patients.Methods: Both newly diagnosed and following IPF patients diagnosed after the previous registry in 2008 were enrolled. Survival analysis was only conducted for patients diagnosed with IPF after 2016 because antifibrotic agents started to be co

APA, Harvard, Vancouver, ISO, and other styles

9

Schuppan, Detlef, Muhammad Ashfaq-Khan, Ai Ting Yang, and Yong Ook Kim. "Liver fibrosis: Direct antifibrotic agents and targeted therapies." Matrix Biology 68-69 (August 2018): 435–51. http://dx.doi.org/10.1016/j.matbio.2018.04.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Pan, Xiaoqi, Xiao Ma, Yinxiao Jiang, et al. "A Comprehensive Review of Natural Products against Liver Fibrosis: Flavonoids, Quinones, Lignans, Phenols, and Acids." Evidence-Based Complementary and Alternative Medicine 2020 (October 5, 2020): 1–19. http://dx.doi.org/10.1155/2020/7171498.

Full text

Abstract:

Liver fibrosis resulting from continuous long-term hepatic damage represents a heavy burden worldwide. Liver fibrosis is recognized as a complicated pathogenic mechanism with extracellular matrix (ECM) accumulation and hepatic stellate cell (HSC) activation. A series of drugs demonstrate significant antifibrotic activity in vitro and in vivo. No specific agents with ideally clinical efficacy for liver fibrosis treatment have been developed. In this review, we summarized the antifibrotic effects and molecular mechanisms of 29 kinds of common natural products. The mechanism of these compounds is

APA, Harvard, Vancouver, ISO, and other styles

More sources

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!